Global circulating tumor cells (CTCs) market is anticipated to grow at a CAGR of 12.5% during the forecast period (2023-2030). An increase in the adoption of CTC detection, including non–invasive techniques used for the detection of cancer is driving industry growth. This technique includes the use of body fluids and their analysis for the determination of cancerous and circulating tumor cells in the patient body. The complex nature of tumors and their heterogenicity, result in a rise in research and development for inventing new techniques, resulting in the growth of the circulating tumor cell market. It is widely accepted that the capture, enumeration, and identification of circulating tumor cells (CTCs) hold significant promise for early cancer screening, diagnosis, and prognosis. According to the National Institute of Health (NIH), in July 2020, The advent of new diagnostic and treatment modalities improved the 5-year relative survival rate for all types of cancers combined the survival rate increased substantially from 39.0% to 70.0% among white patients and from 27.0% up to 63.0% among black patients
Researchers can analyze and characterize enriched CTCs from a molecular perspective with a high level of specificity, gaining valuable insights into how certain tumors progress and disseminate throughout the body. For instance, in February 2021, Menarini-Silicon Biosystems in liquid biopsy and single-cell technologies, launched its innovative CellMag product line for the manual enrichment and staining of rare circulating tumor cells (CTCs). This new product line, composed of the CellMag CTC Epithelial Cell kit, a magnetic tool, and consumables, will allow all liquid biopsy and CTC laboratories to have access to a manual system using the same ferrofluid technology offered by the Gold Standard CELLSEARCH system.
Several new kits capture CTCs from cancers originating in epithelial cells, known as carcinomas. Carcinomas include leading cancer types, such as cancers of the breast, lung, colon, prostate, and bladder. The development of better tools and applications for researchers and clinicians revolutionizing cancer diagnosis through liquid biopsy is also fueling market growth. For instance, in September 2023, nRichDX® launched its new RUO-labeled CTC enrichment kit that uniquely isolates Circulating Tumor Cells (CTCs) from up to 40mL of whole blood samples to help researchers advance liquid biopsy assay research and development.
Various platforms are designed to scan, analyze, and digitally image up to 2 million cells per slide, based on multiple biomarker combinations. In November 2021, Ikonisys Inc. Launched the next generation of CTC Detection and analysis platforms to expand its US presence. The company plans to use the funds to accelerate its commercial development in both the US and Europe and for working capital, with approximately 20.0% of the financing going toward further research and development. Ikoniscope20 is the newest version of the company’s Ikoniscope platform, a fully automated workflow for the automation of fluorescent in situ hybridization assays, and the detection, isolation, and analysis of rare cells, with applications in circulating tumor cell (CTC)-based testing and personalized medicine.
To Request a Sample of our Report on Circulating Tumor Cells Market: https://www.omrglobal.com/request-sample/circulating-tumor-cells-market
Market Coverage
- The market number available for – 2022-2030
- Base year- 2022
- Forecast period- 2023-2030
Segment Covered-
- By Technology
- By Product
- By End Users
Regions Covered-
- North America
- Europe
- Asia-Pacific
- Rest of the World
Competitive Landscape- Bio-Rad Laboratories, Inc., Illumina, Inc., Johnson & Johnson, QIAGEN N.V., Thermo Fisher Scientific Inc., and others.
Circulating Tumor Cells Market Report Segment
By Technology
- CTC Detection and Enrichment Methods
- CTC Direct Detection Methods
- CTC Analysis
By Product
- Kits and Reagents
- Blood Collection Tubes
- Devices
By End Users
- Hospitals and Clinics
- Research and Academic Institutes
- Diagnostic Centers
A full Report of Circulating Tumor Cells Market is Available @ https://www.omrglobal.com/industry-reports/circulating-tumor-cells-market
Circulating Tumor Cells Market Report Segment by Region
North America
- United States
- Canada
Europe
- UK
- Germany
- Spain
- France
- Italy
- Rest of Europe
Asia-Pacific
- India
- China
- Japan
- South Korea
- Rest of APAC
Rest of the World
- Latin America
- Middle East and Africa
Company Profiles
- Advanced Cell Diagnostics
- Akadeum Life Sciences, Inc.
- BIOCEPT, Inc.
- BioFluidica, Inc.
- Biolidics Ltd.
- Creativ MicroTech, Inc.
- Epic Sciences
- Fluxion Biosciences, Inc.
- Ikonisys Inc.
- LineaRx, Inc. (Applied DNA Sciences)
- LungLife AI, Inc.
- Menarini Silicon Biosystems
- Miltenyi Biotec
- OncoDiscover
- Precision Medicine Group, LLC.
- Sysmex Corporation
- ScreenCell
- STEMCELL Technologies, Inc.
Reasons to buy from us –
- We cover more than 15 major industries, further segmented into more than 90 sectors.
- More than 120 countries are for analysis.
- Over 100+ paid data sources mined for investigation.
- Our expert research analysts answer all your questions before and after purchasing your report.
For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/circulating-tumor-cells-market
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services. The company also offer Digital Marketing services through its subsidiary OMR Digital and Software development and Consulting Services through another subsidiary Encanto Technologies.
Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404
